Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: Results from a 1-year, multicentre, open-label, single-arm study in a clinical setting

Applied Health Economics and Health Policy

Volumn 10, Issue 5, 2012, Pages 343-353

  Vender, Ronald ^a,b   Lynde, Charles ^c,d   Ho, Vincent ^e   Chau, Dina ^f   Poulin Costello, Melanie ^f  

^a Dermatrials Research   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Lynde Centre for Dermatology Canada   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Amgen Canada Inc   (Canada)

Author keywords

Etanercept; Plaque psoriasis; Productivity costs; Resource use

Indexed keywords

ETANERCEPT;

ABSENTEEISM; ADULT; AMBULATORY CARE; ARTICLE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; PHYSICAL ACTIVITY; PRODUCTIVITY; PROSPECTIVE STUDY; PSORIASIS VULGARIS; TREATMENT OUTCOME; WORKPLACE;

CANADA; CLINICAL TRIALS, PHASE IV AS TOPIC; ECONOMICS, PHARMACEUTICAL; EFFICIENCY; FEMALE; HEALTH SERVICES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SICK LEAVE; TREATMENT OUTCOME; WORK SCHEDULE TOLERANCE;

EID: 84865530110     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11633980-000000000-00000     Document Type: Article

References (20)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May; 58 (5): 826-50 (Pubitemid 351509656)
2. Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009 Jul; 13 (4): 192-7
3. Lachaine J, Martel M, Langley R, et al. Health care resource utilization by patients with psoriasis [abstract no. P3303]. J Am Acad Dermatol 2009; 60 (3 Suppl. 1): AB162
4. Enbrel® (etanercept): product monograph. Mississauga, ON: Amgen Canada, 2010 Jun 11
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 Nov; 349 (21): 2014-22 (Pubitemid 37448924)
6. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 Jun; 152(6): 1304-12 (Pubitemid 40933433)
7. Moore A, Gordon KB, Kang S, et al. A randomized, openlabel trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 Apr; 56 (4): 598-603 (Pubitemid 46400183)
8. Gelfand JM, Kimball AB, Mostow EN, et al. Patientreported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008 May; 11 (3): 400-7 (Pubitemid 351712967)
9. Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an openlabel study. J Drugs Dermatol 2010 Aug; 9 (8): 928-37
10. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66 (2): e33-45
11. Driessen RJ, Bisschops LA, Adang EM, et al. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010 Jun; 162 (6): 1324-9
12. Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010 Oct; 163 (4): 807-16
13. Vender R, Lynde C, Gillbert M, et al. One-year, multicentre, open-label, single-arm study evaluating real-world safety and effectiveness of etanercept for the treatment of moderateto-severe plaque psoriasis. J Cutan Med Surg. In press
14. Vender R, Lynde C, Gilbert M, et al. Etanercept improves quality-of-life outcomes and treatment satisfaction in patients with moderate-to-severe plaque psoriasis in clinical practice. J Cutan Med Surg. In press
15. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 Nov; 4 (5): 353-65
16. Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat 2011; 22 (6): 337-47
17. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: doubleblind placebo-controlled randomised phase III trial. Lancet 2006 Jan; 367 (9504): 29-35 (Pubitemid 43038667)
18. Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on selfreported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 66 (2): e67-76
19. Zhang W, Bansback N, Guh D, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008 Sep; 35 (9): 1729-36
20. Maksymowych WP, Gooch KL, Wong RL, et al. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010 Feb; 37 (2): 385-92